Speciality Medicines IPO

Listed SME
Min Investment
₹2,48,000
2000 Shares
Min Investment
₹2,48,000 · 2000 Shares
Price Band ₹117–124
Lot Size 1000 shares
Issue Size ₹29 Cr
Listed At ₹124.00 +0%
Subscribed 2.34×
Listed On BSE SME

Speciality Medicines IPO Listing Day Performance

Speciality Medicines listed on BSE SME on 30 March 2026 at ₹124.00, a 0% premium over the issue price of ₹124. A retail investor allotted the minimum application of 2,000 shares (2 lots) gained ₹0 at the listing price.

Issue price
₹124
upper band
Listing price
₹124.00
pre-open auction
Listing gain
+0%
+₹0 per share
Profit per application
+₹0
2,000 shares

GMP vs actual listing

Last GMP before listing₹0 (+0%)
GMP-implied listing₹124
Actual listing₹124.00
Difference+₹0 (+0%)

Demand going into listing

Subscribed overall2.34×
QIB96.24×
NII2.01×
Retail0.85×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
₹0
0.0% ▼ ₹0 since last update
Est. listing ₹124
Upper price ₹124
GMP range —
Updated 17 Mar, 5:07 pm IST Unofficial grey-market data
GMP estimate ₹124
Actual listing ₹124
Listed above the GMP estimate by ₹0 (+0%)
Subscription Status
QIB
96.24x
NII
2.01x
bNII (>10L)
2.70x
sNII (2-10L)
0.64x
Retail
0.85x
Total
2.34x
Updated: Mar 30, 2026 6:08 pm IST
Analysis Score 45 / 100
Mixed Signals
Data: 80%
GMP Score · 44% weight 45
Subscription Score · 38% weight 25
Financial Health · 19% weight 85
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹117–124 per equity share
Face Value₹10 Per Equity Share
Lot Size 1000 shares (Min 2 lots · ₹2,48,000)
Total Issue Size ₹29.14 crore
Fresh IssueEntire issue — no offer for sale, so all proceeds go to the company
Issue TypeBook build Issue
Lead Manager Unicon Capital Services Pvt. Ltd.
Registrar Skyline Financial Services Pvt. Ltd.
Listing atBSE SME
BSE Code7653
Listing Price₹124.00
Listing Gain+0.00%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Total
Each panel has its own scale.
Category Day 1 Day 4 Final Final Final Final Final Final Day 11
QIB 1.00x 1.00x 96.24x 96.24x 96.24x 96.24x 96.24x 96.24x 96.24x
NII 1.41x 1.60x 1.77x 1.77x 1.77x 1.77x 1.77x 1.77x 2.01x
bNII > ₹10L 2.37x 2.68x 2.70x 2.70x 2.70x 2.70x 2.70x 2.70x 2.70x
sNII 2-10L 0.06x 0.10x 0.64x 0.64x 0.64x 0.64x 0.64x 0.64x 0.64x
Retail 0.07x 0.19x 0.85x 0.85x 0.85x 0.85x 0.85x 0.85x 0.85x
Total 0.78x 0.94x 2.19x 2.19x 2.19x 2.19x 2.19x 2.19x 2.34x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 2 2,000 ₹2,48,000
Retail Maximum 2 2,000 ₹2,48,000
S-HNI Minimum 3 3,000 ₹3,72,000
S-HNI Maximum 8 8,000 ₹9,92,000
B-HNI Minimum 9 9,000 ₹11,16,000

IPO Reservation

QIB 1% NII 49.5% Retail 49.5%
Category Shares Offered Shares %
QIB21,0000.95%
NII (HNI)10,89,00049.50%
bNII > ₹10L7,26,00033.00%
sNII < ₹10L3,63,00016.50%
Retail10,90,00049.55%
Total22,00,000

Financial Analysis

Financial Data

ROE
37.85%
ROCE
33.39%
Debt/Equity
0.17
NAV/Share
₹47.07
Revenue Growth
111.64%
Profit Margin
14.71%

Financial Performance

2025 vs 2024 Revenue +111.6% Profit (PAT) +193.9% Total Assets +76.3%
Metric 2024 2025 Oct 2025
Revenue 27.66 58.54 36.93
Expense 23.10 49.85 30.80
Profit (PAT) 2.93 8.61 6.06
Total Assets 22.68 39.98 45.57
Values in Crores (₹)

Peer Comparison

Company EPS P/E Market Cap (Cr)
Remus Pharmaceuticals Limited 65.21 12.25 15
Trident Lifeline Limited 10.22 27.59 18
Mono Pharmacare Limited 1.75 13.87 10
Peer median P/E 13.9x across 3 listed peers

Promoters & Holding Pattern

Promoters: Parth B Goyani and Goyani Sumit Babubhai

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 64,35,796 59.28%
Promoter Holding Post Issue 87,85,796 43.44%

Strengths & Risks

Strengths
  • Strong institutional (QIB) demand — 96.2x.
  • Revenue grew 112% in the latest reported year.
  • Solid profit margin — 14.7%.
  • Strong return on equity — 38%.
  • Low leverage — debt/equity of 0.17.
Risks & Concerns
  • Promoter stake drops to 43% after the issue.
  • Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Speciality Medicines at a glance

From the company's description: “One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic…”

Speciality Medicines is raising ₹29.14 crore through an IPO on the BSE SME. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Setting up of the Research and Development (R&D) Centre (₹13.31 crore), To Meet Working Capital Requirements (₹12 crore) and Product registration in the international markets (₹2.89 crore).

Revenue went from ₹27.66 crore in 2024 to ₹58.54 crore in 2025, up 112% over 1 year. Profit after tax went from ₹2.93 crore to ₹8.61 crore, a net margin of 15% in the latest year.

The promoter, Parth B Goyani and Goyani Sumit Babubhai, holds 59% before the issue and 43% after it — a dilution of 15.8 percentage points. Debt stands at 0.17 times equity.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Speciality Medicines Ltd., 913, One World West, S. No. 396, FP 119,, Village- Vejalpur, Ahmadabad City,, Ahmedabad, Gujarat, India,, Ahmedabad, Gujarat, 380051

Objects of the Issue

Purpose Amount (Cr)
Setting up of the Research and Development (R&D) Centre 13.31
Product registration in the international markets 2.89
Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company 1.75
To Meet Working Capital Requirements 12.00
General Corporate Purpose -

Resources & Documents

Speciality Medicines IPO - Quick Take

Speciality Medicines has set a price band of Rs 117–Rs 124 per share for an issue size of Rs 29 crore. The stock listed flat against its issue price.

The issue is promoted by Parth B Goyani and Goyani Sumit Babubhai with Unicon Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards setting up of the Research and Development (R&D) Centre (Rs 13 crore) and product registration in the international markets (Rs 3 crore).

On fundamentals, the company is posting revenue growth of 111.6%, a profit margin of 14.7%, return on equity of 37.9% in its most recent reported period. Listed peers in this segment include Trident Lifeline Limited (P/E 27.59x, market cap Rs 18 crore) and Remus Pharmaceuticals Limited (P/E 12.25x, market cap Rs 15 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Speciality Medicines IPO: Lead Manager & Registrar Track Record

How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Speciality Medicines itself, so they describe what came before it.

SME IPOs, last 12 months
  • Speciality Medicines listed at +0% on day one; the median of 193 listings was +1.7% (better than 30% of them).
  • Subscribed 2.34x against a median of 4.03x across 192 issues (higher than 40%).
  • Average listing-day move across all 194 SME listings we track: +11.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Unicon Capital Services Pvt. Ltd. Lead manager 1 1 MB · 0 SME 100% 1 of 1 +65.3% +65.3%
Skyline Financial Services Pvt. Ltd. Registrar 16 0 MB · 16 SME 69% 11 of 16 Check allotment →
Recent listings managed by Unicon Capital Services Pvt. Ltd. (1)
IPOListedListing-day move
BLS Polymers 03 Nov 2026 +65.3%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Speciality Medicines listed at Rs 124.00 on 30 March 2026, against an issue price of Rs 124 — a 0% premium.

+0% at the listing price — Rs 0 per share, or Rs 0 on the minimum retail application of 2,000 shares.

The price band of Speciality Medicines IPO is Rs 117 to Rs 124 per share. Face value is Rs 10 per share.

The total issue size of Speciality Medicines IPO is Rs 29 crore, comprising fresh issue of Rs 29 crore.

The lot size of Speciality Medicines IPO is 1,000 shares. The minimum application is 2 lots (2,000 shares), requiring an investment of Rs 2,48,000.

Speciality Medicines IPO opens for subscription on March 20, 2026 and closes on March 24, 2026.

The expected allotment date for Speciality Medicines IPO is March 25, 2026. Refunds for unsuccessful applicants are expected on March 27, 2026.

Speciality Medicines IPO is scheduled to list on March 30, 2026 on BSE. BSE script code: 7653, ISIN: –.

The last GMP (Grey Market Premium) recorded for Speciality Medicines IPO before listing was +Rs 0 (+0.0% over issue price). The shares actually listed at Rs 124 (+0.00% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Speciality Medicines IPO was subscribed 2.34 times overall by the close of bidding — retail at 0.85x, QIB at 96.24x, NII at 2.01x.

Based on the final retail subscription of 0.85x for Speciality Medicines IPO, the estimated retail allotment probability is approximately 100.0%. This is a high probability of allotment.

The registrar for Speciality Medicines IPO is Skyline Financial Services Pvt. Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Speciality Medicines IPO are Unicon Capital Services Pvt. Ltd.

The promoter(s) of Speciality Medicines are Parth B Goyani and Goyani Sumit Babubhai.

Speciality Medicines IPO GMP — What It Means

See the full Speciality Medicines GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Speciality Medicines
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate